Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07175038 · ClinicalTrials.gov registry record · Phase 2

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

A Phase 2 study of Pulmonary Arterial Hypertension PAH and Pulmonary Hypertension, Interstitial Lung Disease, sponsored by AllRock Bio.

Recruiting
Registry status
Phase 2
Development phase
40
Enrollment target
11
Study locations

NCT07175038: Recruiting Phase 2 study of Pulmonary Arterial Hypertension PAH and Pulmonary Hypertension, Interstitial Lung Disease, sponsored by AllRock Bio.

NCT07175038 is a Phase 2 study of Pulmonary Arterial Hypertension PAH and Pulmonary Hypertension, Interstitial Lung Disease that is actively recruiting participants, run by AllRock Bio. The registered enrollment target is 40 participants, roughly in line with the 40-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target. The trial reports 11 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07175038, a Phase 2 study of Pulmonary Arterial Hypertension PAH and Pulmonary Hypertension, Interstitial Lung Disease, is actively recruiting participants, sponsored by AllRock Bio.

RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
11
Study locations

Study Summary

This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by a long-term extension period of the study through the end of the program or marketing approval/authorization.

Primary Outcome

Each participant's PVR, at resting supine, was measured by Right Heart Catheterization (RHC) at baseline and at 24 weeks.

Conditions Studied

Pulmonary Arterial Hypertension PAH Pulmonary Hypertension, Interstitial Lung Disease

Interventions

  • DRUG ROC-101

Study Locations (11)

Arizona

  • Arizona Pulmonary Specialists - Phoenix

Colorado

  • University of Colorado - Aurora

Florida

  • Mayo Clinic of Florida - Jacksonville

Kansas

  • The University of Kansas Medical Center Research Institute - Kansas City

Michigan

  • University of Michigan - Ann Arbor

Ohio

  • Ohio State University - Columbus

Oregon

  • Bend Memorial Clinic - Bend

Pennsylvania

  • Temple University - Philadelphia

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2025-10-01
Est. Completion 2029-03
Phase Phase 2
AllRock Bio

1 total trials

What NCT07175038 shows while recruiting

NCT07175038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, roughly in line with the 40-participant average among 5 other Pulmonary Arterial Hypertension PAH trials with a reported enrollment target.

The record links to 2 conditions, with Pulmonary Arterial Hypertension PAH appearing as the primary indexed condition, and to 1 intervention - of which ROC-101 is the first listed.

NCT07175038 lists 11 locations in 11 states (Arizona, Colorado, Florida).

Frequently Asked Questions

What is clinical trial NCT07175038 about?

NCT07175038 is a clinical study titled "A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)". This study evaluates the effect of ROC-101 in adults with either Pulmonary Arterial Hypertension (PAH) or Pulmonary Hypertension Associated with Interstitial Lung Disease (ILD-PH). Each eligible participant will receive standard of care (SOC) plus ROC-101 for a 24-week treatment period, followed by ...

What is the current status of trial NCT07175038?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-10-01. Estimated completion is 2029-03.

What conditions does trial NCT07175038 study?

This clinical trial studies the following conditions: Pulmonary Arterial Hypertension PAH, Pulmonary Hypertension, Interstitial Lung Disease.

What interventions are being tested in trial NCT07175038?

The interventions under investigation include: ROC-101 (DRUG).

Who is sponsoring clinical trial NCT07175038?

This trial is sponsored by AllRock Bio, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07175038 being conducted?

This trial has 11 study locations across Arizona, Colorado, Florida, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Pulmonary Arterial Hypertension PAH

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT07175038

Source: ClinicalTrials.gov NCT07175038, the US trial registry maintained by the National Library of Medicine. NCT07175038 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.